{"id":"W3211577173","doi":"10.1016/j.jtho.2021.10.023","title":"CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"ca_institutions":"Humber River Regional Hospital; Centre Hospitalier de l’Université de Montréal; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Windsor Regional Hospital; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Alberta Cancer Foundation; Sunnybrook Health Science Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Canadian Cancer Society Research Institute; Takeda Canada; Merck Sharp and Dohme; Cancer Australia; Astellas Pharma Canada; AbbVie; Roche; Novartis; Sanofi; Merck; Boehringer Ingelheim; Amgen; Pfizer; Celgene; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Platinum; Immunotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006499101,0.0001649838,0.001479106,0.0002232395,0.00003027496,0.00001078318,0.00004529479,0.00006203692,0.0001529557],"category_scores_gemma":[0.0002547618,0.00008672327,0.0001108746,0.0002730775,0.0001569985,0.00009455266,0.000006951414,0.0001949794,3.034127e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002671368,"about_ca_system_score_gemma":0.002701197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002032934,"about_ca_topic_score_gemma":0.0000885906,"domain_scores_codex":[0.9981831,0.000362915,0.0007144411,0.0001589998,0.0004210312,0.0001595148],"domain_scores_gemma":[0.9978828,0.0004204954,0.0008303018,0.0001455897,0.0006007181,0.0001201293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9346077,0.004984434,0.003160119,0.0001014842,0.001152061,0.0004124086,0.0009260682,0.00002832236,0.000098347,0.000004143471,0.0000373886,0.05448752],"study_design_scores_gemma":[0.9690902,0.02366592,0.001888989,0.0004796817,0.00264465,0.0002423516,0.0004005231,0.0002363244,0.0008467377,0.0000288285,0.0003775996,0.00009817378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959608,0.0002469926,0.0009532592,0.001259732,0.0001071287,0.001124191,0.00001660896,0.00000494464,0.0003263044],"genre_scores_gemma":[0.9817136,0.00005027732,0.01766392,0.0002755719,0.00005679921,0.00003204162,0.00001691587,0.0000233006,0.0001676017],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05438934,"threshold_uncertainty_score":0.4791807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02016332716884563,"score_gpt":0.4295004179541777,"score_spread":0.4093370907853321,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}